Taich Adam
Known title: Chief Financial OfficerCIK: 0001971187
Associated companies
Transaction History
| TXG | ▼ Sell | Open Market | 31,428 | $2.0M | 9/9/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 13,754 | $898K | 9/9/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 1,206 | $77K | 9/9/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 17,166 | $1.1M | 8/24/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 15,098 | $369K | 5/22/2026 | View on chart |
| TXG | ▲ Buy | Grant | 106,579 | $0 | 2/26/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 8,968 | $167K | 2/23/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 11,888 | $226K | 11/24/2025 | View on chart |
| TXG | ▼ Sell | Open Market | 22,315 | $308K | 8/22/2025 | View on chart |
| TXG | ▼ Sell | Open Market | 4,044 | $34K | 5/22/2025 | View on chart |
| TXG | ▲ Buy | Grant | 133,928 | $0 | 3/17/2025 | View on chart |
| TXG | ▲ Buy | Grant | 201,704 | $0 | 10/23/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.